193 related articles for article (PubMed ID: 25115546)
1. Intravenous immunoglobulins for Alzheimer's disease.
Puli L; Tanila H; Relkin N
Curr Alzheimer Res; 2014; 11(7):626-36. PubMed ID: 25115546
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials of intravenous immunoglobulin for Alzheimer's disease.
Relkin N
J Clin Immunol; 2014 Jul; 34 Suppl 1():S74-9. PubMed ID: 24760112
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin reduces tau pathology and preserves neuroplastic gene expression in the 3xTg mouse model of Alzheimer's disease.
Counts SE; Perez SE; He B; Mufson EJ
Curr Alzheimer Res; 2014; 11(7):655-63. PubMed ID: 25156574
[TBL] [Abstract][Full Text] [Related]
4. Aβ anti-idiotypic antibodies are present in intravenous immunoglobulin and are produced in mice following its administration.
Loeffler DA; Klaver AC; Coffey MP
Autoimmunity; 2015 Jun; 48(4):196-200. PubMed ID: 25392130
[TBL] [Abstract][Full Text] [Related]
5. Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease.
Kasai T; Kondo M; Ishii R; Tanaka A; Ataka S; Shimada H; Tomiyama T; Mori H; Taylor M; Allsop D; Nakagawa M; Mizuno T; Tokuda T
PLoS One; 2017; 12(4):e0174630. PubMed ID: 28394917
[TBL] [Abstract][Full Text] [Related]
6. Naturally occurring autoantibodies against Aβ oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin.
Wang T; Xie XX; Ji M; Wang SW; Zha J; Zhou WW; Yu XL; Wei C; Ma S; Xi ZY; Pang GL; Liu RT
Neuropharmacology; 2016 Jun; 105():561-576. PubMed ID: 26907803
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin and Alzheimer's disease immunotherapy.
Solomon B
Curr Opin Mol Ther; 2007 Feb; 9(1):79-85. PubMed ID: 17330405
[TBL] [Abstract][Full Text] [Related]
8. Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?
Loeffler DA
J Neuroinflammation; 2014 Dec; 11():198. PubMed ID: 25476011
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.
Dodel R; Neff F; Noelker C; Pul R; Du Y; Bacher M; Oertel W
Drugs; 2010 Mar; 70(5):513-28. PubMed ID: 20329802
[TBL] [Abstract][Full Text] [Related]
10. Concentrations of antibodies against β-amyloid 40/42 monomer and oligomers in Chinese intravenous immunoglobulins.
Ye S; Zeng R; Jiang P; Hou M; Liu F; Wang Z; Du X; Yuan J; Chen Y; Cao H; Ma L; Li C
J Pharm Biomed Anal; 2017 May; 138():277-282. PubMed ID: 28231531
[TBL] [Abstract][Full Text] [Related]
11. Comparison of ELISA measurements of anti-Aβ concentrations and percentages of specific binding to Aβ between unfractionated intravenous immunoglobulin products and their purified anti-Aβ antibodies.
Klaver AC; Coffey MP; Smith LM; Loeffler DA
Immunol Lett; 2013; 154(1-2):7-11. PubMed ID: 23928186
[TBL] [Abstract][Full Text] [Related]
12. ELISA measurement of specific antibodies to phosphorylated tau in intravenous immunoglobulin products.
Loeffler DA; Klaver AC; Coffey MP
Int Immunopharmacol; 2015 Oct; 28(2):1108-12. PubMed ID: 26330100
[TBL] [Abstract][Full Text] [Related]
13. Antibody Assay and Anti-Inflammatory Function Evaluation of Therapeutic Potential of Different Intravenous Immunoglobulins for Alzheimer's Disease.
Fei Z; Pei R; Pan B; Ye S; Zhang R; Ma L; Wang Z; Li C; Du X; Cao H
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982622
[TBL] [Abstract][Full Text] [Related]
14. Role of complement systems in IVIG mediated attenuation of cognitive deterioration in Alzheimer's disease.
Gong B; Levine S; Barnum SR; Pasinetti GM
Curr Alzheimer Res; 2014; 11(7):637-44. PubMed ID: 25115545
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin reduces β amyloid and abnormal tau formation caused by herpes simplex virus type 1.
Wozniak MA; Itzhaki RF
J Neuroimmunol; 2013 Apr; 257(1-2):7-12. PubMed ID: 23385080
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulins for Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease: A systematic review with meta-analysis.
Liu J; Wang LN
Expert Rev Neurother; 2019 Jun; 19(6):475-480. PubMed ID: 31092051
[No Abstract] [Full Text] [Related]
18. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
[TBL] [Abstract][Full Text] [Related]
19. Amyloid-β concentration and structure influences the transport and immunomodulatory effects of IVIG.
Wuest DM; Lee KH
J Neurochem; 2014 Jul; 130(1):136-44. PubMed ID: 24517534
[TBL] [Abstract][Full Text] [Related]
20. Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations.
Klaver AC; Finke JM; Digambaranath J; Balasubramaniam M; Loeffler DA
Int Immunopharmacol; 2010 Jan; 10(1):115-9. PubMed ID: 19840873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
